• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 909-923 of 973 results

... PhD Re garding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122...

Document IPR2023-00724, No. 2652 Exhibit - EX2652 Excerpt of Reply Expert Report of William J Jusko, PhD Re garding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122

cite Cite Document

1134 Exhibit: Exhibit 1134 39th Orange Book

Document IPR2023-00724, No. 1134 Exhibit - Exhibit 1134 39th Orange Book (P.T.A.B. May. 22, 2024)

cite Cite Document

1306 Exhibit: Exhibit 1306 Coca Decl

Document IPR2023-00724, No. 1306 Exhibit - Exhibit 1306 Coca Decl (P.T.A.B. May. 22, 2024)

cite Cite Document

2376 Exhibit: EX2376 Kalra, S, Sodium Glucose Co Transporter 2 SGLT2 Inhibitors...

Document IPR2023-00724, No. 2376 Exhibit - EX2376 Kalra, S, Sodium Glucose Co Transporter 2 SGLT2 Inhibitors A Review of Their Basic and Clinical Pharmacology, Diabetes Ther, 2014 Dec 52355 36...

cite Cite Document

2499 Exhibit: EX2499 Novo Nordisk, Financial report for the period 1 January 2019...

Document IPR2023-00724, No. 2499 Exhibit - EX2499 Novo Nordisk, Financial report for the period 1 January 2019 to 30 June 2019 Aug 9, 2019 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2107 Exhibit: EX2107 Ozempic FDA Approval Letter for sNDA March 28, 2022

Document IPR2023-00724, No. 2107 Exhibit - EX2107 Ozempic FDA Approval Letter for sNDA March 28, 2022 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2502 Exhibit: EX2502 Novo Nordisk, Financial report for the period 1 January 2020...

Document IPR2023-00724, No. 2502 Exhibit - EX2502 Novo Nordisk, Financial report for the period 1 January 2020 to 31 March 2020 May 6, 2020 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2523 Exhibit: EX2523 Eli Lilly Co, SEC Form 10 K for the Year Ended December 31...

Document IPR2023-00724, No. 2523 Exhibit - EX2523 Eli Lilly Co, SEC Form 10 K for the Year Ended December 31, 2022 Feb 22, 2023 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2384 Exhibit: EX2384 Clamp, LD, et al, Enhanced insulin sensitivity in successful, l...

Document IPR2023-00724, No. 2384 Exhibit - EX2384 Clamp, LD, et al, Enhanced insulin sensitivity in successful, long term weight loss maintainers compared with matched controls with no weight loss his...

cite Cite Document

2432 Exhibit: EX2432 Invokana® Prescribing Information rev July 2017

Document IPR2023-00724, No. 2432 Exhibit - EX2432 Invokana® Prescribing Information rev July 2017 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2417 Exhibit: EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb compl...

Document IPR2023-00724, No. 2417 Exhibit - EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb complete expansion of diabetes alliance through Bristol Myers Squibb’s acquisition of Amylin P...

cite Cite Document

2504 Exhibit: EX2504 Novo Nordisk, Financial report for the period 1 January 2020...

Document IPR2023-00724, No. 2504 Exhibit - EX2504 Novo Nordisk, Financial report for the period 1 January 2020 to 30 September 2020 Oct 30, 2020 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2501 Exhibit: EX2501 Novo Nordisk, Financial report for the period 1 January 2019...

Document IPR2023-00724, No. 2501 Exhibit - EX2501 Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 Feb 5, 2020 (P.T.A.B. Jan. 17, 2024)

cite Cite Document

2064 Exhibit: EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly C...

Document IPR2023-00724, No. 2064 Exhibit - EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly Co,” available at httpssynapsepatsnapcomdrug482a547adeba4170ab23efa225fb966d l...

cite Cite Document

1102 Exhibit: Exhibit 1102 Rubio Herrera

Document IPR2023-00724, No. 1102 Exhibit - Exhibit 1102 Rubio Herrera (P.T.A.B. May. 22, 2024)

cite Cite Document
<< 1 2 3 4 5 ... 61 62 63 64 65 ... >>